- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 21:46 | Invivyd reveals plans to test an antibody drug against measles | ||
| 18:46 | Chasing a tough-to-treat lung disease, Avalyn plans an IPO | ||
| 17:46 | Lilly launches GLP-1 pill, kicking off showdown with Novo Nordisk | ||
| Mi | Sidewinder secures $137M to advance 'precision' ADCs | ||
| Mi | With 3 quick buyouts, Gilead leans into its latest transformation | ||
| Mi | Activist investor revives campaign to overhaul Novavax board | ||
| Mi | Novo underprices Lilly with higher-dose Wegovy; Insmed absorbs 'expected' study failure | ||
| Mi | Jeito Capital, prominent biotech investor, raises $1.2B for next fund | ||
| Di | Terns rebuffed a higher bid before selling to Merck | ||
| Di | Gilead continues M&A surge with $3.1B deal for ADC specialist Tubulis | ||
| Di | Sanofi immune drug hopeful posts mixed results in mid-stage tests | ||
| Mo | Hims & Hers says limited data stolen in social engineering attack | ||
| Mo | Under-the-skin Tepezza comparable to infused version in key study, Amgen says | ||
| Mo | FDA floats new clinical trial reforms; Takeda punts Denali brain drug | ||
| Mo | Neurocrine to acquire Prader-Will drug in $2.9B Soleno buyout | ||
| Mo | Perks persuade participants | ||
| Fr | Trump revives pharma tariffs with 100% charges, but leaves loopholes | ||
| 02.04. | Immunovant eye drug flunks Phase 3 studies; Beam sickle cell data published in NEJM | ||
| 01.04. | Biogen, on the heels of a $5.6B buyout, turns its sights to early-stage assets | ||
| 01.04. | FDA approves Lilly obesity pill, triggering battle with Novo Nordisk | ||
| 01.04. | Ambrosia adds a megaround for obesity drugs | ||
| 01.04. | A 'hijacked plane': CDC, under RFK Jr.'s influence, trades science for dogma | ||
| 01.04. | FDA, after turbulent year, leaves drugmakers guessing on its direction | ||
| 31.03. | Lilly beefs up neuroscience pipeline with $6.3B Centessa buyout | ||
| 31.03. | Biogen, with $5.6B Apellis buy, builds out immunology offerings |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.